DSIP (Delta Sleep-Inducing Peptide)
Also known as: DSIP, Delta Sleep Peptide, Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu
Grey-Market Compound. This compound is not approved by the FDA or any major regulatory authority. No established regimen exists. Products available outside of regulated channels lack standardized manufacturing, quality control, and potency verification. Consult a qualified clinician. Research-only risks apply.
Overview
Clinical Summary
Delta sleep-inducing peptide (DSIP) is a nonapeptide originally isolated from rabbit cerebral venous blood during electrically induced sleep in 1977. Despite its name, subsequent research has shown inconsistent effects on sleep architecture, and its true physiological role remains unclear. DSIP may function more as a stress-modulatory and neuroendocrine peptide than a direct sleep inducer. Some studies have reported subjective improvements in sleep quality and reductions in stress hormones, but results have been highly variable across studies. The mechanism of action is poorly defined and no receptor has been conclusively identified.
Plain Language Summary
DSIP (Delta Sleep-Inducing Peptide) is a small peptide that was discovered in rabbit brain fluid during induced sleep. Despite its name, research has shown inconsistent results for actually improving sleep. Some people report better sleep quality, but the scientific evidence is weak and contradictory. Its mechanism of action is not well understood. It is available through grey-market sources but has no regulatory approval.
Mechanism of Action
The mechanism of DSIP remains poorly characterized. No specific receptor has been conclusively identified, though DSIP has been shown to interact with multiple neurotransmitter systems. Proposed mechanisms include: modulation of GABAergic transmission, alteration of serotonin and norepinephrine turnover, regulation of corticotropin-releasing hormone (CRH) secretion, and modification of opioid peptide release. DSIP may act as a modulatory peptide that influences the balance between stress and restorative states rather than directly inducing sleep. It has been shown to normalize disturbed sleep patterns in some animal models without affecting normal sleep architecture.
Evidence Summary
Schneider-Helmert and Schoenenberger (1983) reported variable effects on sleep in human volunteers and insomnia patients, with some subjects showing improved subjective sleep quality and reduced cortisol. Graf and Kastin (1986) reviewed the literature and noted highly inconsistent results across studies. Some studies reported benefits in chronic insomnia, alcohol and opioid withdrawal, and stress-related conditions, but methodological quality was generally poor. No well-designed, adequately powered RCT has been conducted. The field has largely stalled due to irreproducible results.
Safety Profile
Limited safety data are available. In the small studies conducted, DSIP appeared to be well tolerated with no serious adverse events reported. However, the small sample sizes and short durations preclude meaningful safety conclusions. The poorly defined mechanism makes risk prediction difficult. No formal toxicology studies have been published.
Contraindications
- No established contraindications due to insufficient data
- Caution in patients with endocrine disorders (neuroendocrine modulation)
- Pregnancy and breastfeeding (no safety data)
Adverse Events
- No consistent adverse events identified in published studies
- Headache (occasional, in some studies)
- The limited data preclude comprehensive adverse event characterization
Interactions
- Theoretical interaction with sedatives and hypnotics
- May modulate opioid system (theoretical interaction with opioid analgesics)
- No formal interaction studies
Regulatory Notes
DSIP has no regulatory approval in any jurisdiction. It has not entered clinical trials since the 1980s/1990s. Available through grey-market peptide vendors. The poorly defined mechanism and inconsistent results have deterred pharmaceutical development.
Monitoring Considerations
No established monitoring guidelines. Sleep quality questionnaires (Pittsburgh Sleep Quality Index) and polysomnography could be used to assess response in research settings. Cortisol and stress hormone levels may be relevant given proposed neuroendocrine effects.
These are general considerations for clinical awareness and do not constitute prescriptive monitoring recommendations for any individual patient.
Stability and Handling Notes
Grey-market preparations are supplied as lyophilized powder. DSIP is reported to have relatively poor stability in solution. Store lyophilized at minus 20 degrees C. Reconstitute with bacteriostatic water and use promptly. No pharmacopeial stability standards exist.
References
- 1review
Delta Sleep-Inducing Peptide (DSIP): An Update on Its Structure, Function, and Clinical Potential
Graf MV, Kastin AJ. (1986). Neuroscience & Biobehavioral Reviews
Key findings: Review of DSIP pharmacology. While initially isolated as a sleep factor from rabbit cerebral venous blood, subsequent studies showed inconsistent effects on sleep architecture. DSIP may modulate stress responses, pain perception, and endocrine function rather than directly inducing sleep.
Limitations: Inconsistent results across studies. Mechanism poorly defined. Limited controlled human data.
- 2preclinical
Effects of DSIP on Sleep, Stress Hormones, and Pain Modulation
Schneider-Helmert D, Schoenenberger GA. (1983). European Neurology
Key findings: DSIP administration in human volunteers and insomnia patients showed variable effects on sleep latency and quality. Some subjects showed improved subjective sleep quality and reduced cortisol levels.
Limitations: Small sample sizes. Inconsistent methodology across studies. No clear dose-response relationship. Results not replicated reliably.
Last reviewed: 2026-03-24 | Version: 1 | Status: Published
More in Other
VIP (Vasoactive Intestinal Peptide)
VIP · Vasoactive Intestinal Polypeptide · Aviptadil (synthetic VIP)
VIP (Vasoactive Intestinal Peptide) is a natural signaling molecule in your body that reduces inflammation, relaxes blood vessels, and regulates immune function. It is best known in integrative medicine for treating chronic inflammatory response syndrome (CIRS), a condition caused by biotoxin exposure from mold. In the Shoemaker protocol, VIP nasal spray is used as a final treatment step. While the science behind VIP is promising, most of the evidence comes from small studies and animal research.
Oxytocin
Pitocin · Syntocinon · OXT
Oxytocin is often called the 'bonding hormone.' It is a natural hormone released during childbirth, breastfeeding, and social bonding. The FDA-approved form (Pitocin) is used in hospitals to induce labor and control bleeding after delivery. Researchers have also studied oxytocin nasal spray for social anxiety, autism, and relationship bonding, but results have been inconsistent. While oxytocin clearly plays an important role in social behavior, supplementing it with a nasal spray does not reliably produce the expected effects.
Snap-8
Acetyl Octapeptide-3 · SNAP-8 · Acetyl Glutamyl Heptapeptide-1
Snap-8 is a peptide used in anti-aging skincare products that claims to work like a topical version of Botox. The idea is that it blocks the same nerve signaling system that Botox targets, reducing muscle contractions that cause wrinkles. However, this has only been shown to work in laboratory cell cultures. No clinical studies have proven that Snap-8 actually reduces wrinkles when applied to skin, and it is unclear whether it can penetrate deep enough to reach the nerve-muscle connections where it would need to act.
Want to discuss this compound with a qualified physician?
The Peptide Association has verified over 160 licensed providers specializing in peptide therapy, with telehealth options available in most states.
Find a Verified Provider